Association between inflammatory biomarker serum procalcitonin and obesity in women with polycystic ovary syndrome

Journal of Reproductive Immunology

Volumn 97, Issue 2, 2013, Pages 232-239

  Rashad, Nearmeen M ^a   El Shal, Amal S ^a   Abdelaziz, Ahmed M ^b  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b BENHA UNIVERSITY   (Egypt)

Author keywords

High sensitivity C reactive protein; Inflammation; Polycystic ovary syndrome; Procalcitonin

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FOLLITROPIN; LUTEINIZING HORMONE; PROCALCITONIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; NEUTROPHIL COUNT; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST HIP RATIO;

ADULT; BIOLOGICAL MARKERS; BODY COMPOSITION; BODY MASS INDEX; C-REACTIVE PROTEIN; CALCITONIN; CASE-CONTROL STUDIES; CHOLESTEROL; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; OBESITY; POLYCYSTIC OVARY SYNDROME; PROTEIN PRECURSORS; TRIGLYCERIDES; WAIST-HIP RATIO;

EID: 84875256121     PISSN: 01650378     EISSN: 18727603     Source Type: Journal    
DOI: 10.1016/j.jri.2012.10.007     Document Type: Article

References (34)

1. Abbasi A., Corpeleijn E., Postmus D., Gansevoort R.T., de Jong P.E., Gans R.O., Struck J., Hillege H.J., Stolk R.P., Navis G., Bakker S.J. Plasma procalcitonin is associated with obesity, insulin resistance, and the metabolic syndrome. J. Clin. Endocrinol. Metab. 2010, 95:26-31.
2. Asunción M., Calvo R.M., San Millán J.L., Sancho J., Avila S., Escobar-Morreale H.F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab. 2000, 85:2434-2438.
3. Azziz R., Woods K.S., Reyna R., Key T.J., Knochenhauer E.S., Yildiz B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 2004, 89(6):2745-2749.
4. Becker K.L., Nylén E.S., White J.C., Muller B., Snider R.H. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J. Clin. Endocrinol. Metab. 2004, 89:1512-1525.
5. Becker K.L., Snider R., Nylen E.S. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit. Care Med. 2008, 36:941-952.
6. Boulman N., Levy Y., Leiba R., Shachar S., Linn R., Zinder O., Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J. Clin. Endocrinol. Metab. 2004, 89(5):2160-2165.
7. Briel M., Schuetz P., Mueller B., Young J., Schild U., Nusbaumer C., Périat P., Bucher H.C., Christ-Crain M. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch. Intern. Med. 2008, 168:2000-2007. discussion 2007-2008.
8. Carmina E., Bucchierri S., Esposito A., Del Puente A., Mansueto P., Orio F., et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of it relation to insulin resistance. J. Clin. Endocrinol. Metab. 2007, 92:2500-2505.
9. Carmina E. Genetic and environmental aspects of polycystic ovary syndrome. J. Endocrinol. Invest. 2003, 26:1151-1159.
10. Corton M., Botella-Carretero J.I., Benguria A., et al. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2007, 92(1):328-337.
11. Ehrmann D.A. Polycystic ovary syndrome. N. Engl. J. Med. 2005, 352(12):1223-1236.
12. Escobar-Morreale H.F., Villuendas G., Botella-Carretero J.I., Alvarez-Blasco F., Stanchion R., Luque-Ramírez M., San Millán J.L. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum. Reprod. 2006, 21(9):2257-2265.
13. Fenkci V., Fenkci S., Yilmazer M., Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil. Steril. 2003, 80:123-127.
14. Forouhi N.G., Sattar N., McKeigue P.M. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int. J. Obes. Relat. Metab. Disord. 2001, 25:1327-1331.
15. Frieldewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18:499-502.
16. González F., Rote N.S., Minium J., Kirwan J.P. Increased activation of nuclear factor κβ triggers inflammation and insulin resistance in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2006, 91:1508-1512.
17. González F., Rote N.S., Minium J., Kirwan J.P. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism 2009, 58:954-962.
18. Heutling D., Schulz H., Nickel I., Kleinstein J., Kaltwasser P., Westphal S., Friedrich Mittermayer F., Wolzt M., Krzyzanowska K., Randeva H., Schernthaner G., Lehnert H. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J. Clin. Endocrinol. Metab. 2008, 93:82-90.
19. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., Quon M.J. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 2000, 85:2402-2410.
20. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 2004, 89:2548-2556.
21. Li X., Lin J.F. Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome. Zhonghua Yi Xue Za Zhi. 2005, 85(46):3266-3271.
22. Limper M., de Kruif M.D., Duits A.J., Brandjes D.P., van Gorp E.C. The diagnostic role of procalcitonin and other biomarkers in discriminating infectious from noninfectious fever. J. Infect. 2010, 60:409-416.
23. Linscheid P., Seboek D., Nylen E.S., Langer I., Schlatter M., Becker K.L., Keller U., Muller B. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology 2003, 144:5578-5584.
24. Linscheid P., Seboek D., Schaer D.J., Zulewski H., Keller U., Muller B. Expression and secretion of procalcitonin and calcitonin generelated peptide by adherent monocytes and by macrophage-activated adipocytes. Crit. Care Med. 2004, 32:1715-1721.
25. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
26. Monga A. Disorders of Menstrual Cycle. Gnaecology by Ten Teachers 2006, Hodder Arnold 18th edition Ltd, Chennai, pp. 43-58, Chapter 5, www.scribd.com/doc/Gynaecology-by-10-Teachers-18th-Edition.
27. Mueller B., White J.C., Nylen E.S., Snider R.H., Becker K.L., Habener J.F. Ubiquitous expression of the calcitonin I gene in multiple tissues in response to sepsis. J. Clin. Endocrinol. Metab. 2001, 86(1):396-404.
28. Puder J.J., Varga S., Kraenzlin M., De Geyter C., Keller U., Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J. Clin. Endocrinol. Metab. 2005, 90:6014-6021.
29. Repaci A., Gambineri A., Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol. Cell. Endocrinol. 2011, 335(1):30-41.
30. Samy N., Hashim M., Sayed M., Said M. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis. Markers 2009, 26(4):163-170.
31. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004, 19(1):41-47. The Rotterdam ESHRE-ASRM-sponsored PCOS Consensus Workshop Group.
32. Tschaikowsky K., Hedwig-Geissing M., Braun G., Radespiel-Troeger M. Predictive value of procalcitonin, interleukin-6, and C-reactive protein for survival in postoperative patients with severe sepsis. J. Crit. Care 2010, 26:54-64.
33. Wehr E., Möller R., Horejsi R., Giuliani A., Kopera D., Schweighofer N., Groselj-Strele A., Pieber T.R., Obermayer-Pietsch B. Subcutaneous adipose tissue topography and metabolic disturbances in polycystic ovary syndrome. Wien. Klin. Wochenschr. 2009, 121:262-269.
34. Xu X.F., De Per gola G., Bjorntorp P. Testosterone increases lipolysis and the number of beta-adrenoceptors in male rat adipocytes. Endocrinology 1991, 128(1):379-382.